A Phase I Study of Pembrolizumab Anti PD-1 Monoclonal Antibody in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 09 Jul 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms PARIS
- 04 Jul 2019 Planned End Date changed from 1 Nov 2020 to 1 Aug 2020.
- 04 Jul 2019 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
- 04 Jul 2019 Status changed from discontinued to withdrawn prior to enrolment.